51视频

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 51视频 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • 51视频

    51视频

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Oct 1 2019

Full Issue

Pharmacy Chains CVS, Walgreens, Rite Aid Remove Zantac From Store Shelves Over Cancer Concerns

The FDA is investigating the source of the contamination in the popular heartburn drug.

The pharmacy chains Walgreens, Rite Aid and CVS have moved to stop selling the heartburn medicine Zantac and its generic versions after the Food and Drug Administration warned this month that it had detected low levels of a cancer-causing chemical in samples of the drug. A Walgreens spokesman said in a statement on Monday that the company had pulled the drug from its shelves 鈥渨hile the FDA continues its review of the products.鈥 A Rite Aid spokesman said the company was 鈥渋n the process of removing Zantac and generic versions sold under the Rite Aid name from its shelves.鈥 (Garcia, 9/30)

The decision by the pharmacy giants adds to a flurry of worldwide concern about the drug. Major manufacturers of the generic form, ranitidine, have announced recalls, and other countries have requested that companies halt distribution of the drug or issued recalls. The U.S. Food and Drug Administration has been investigating the possible risk to patients, as well. (Johnson and Bellware, 9/30)

Some Zantac products, known in generic form as ranitidine, have been recalled in the U.S. by manufacturers. Pharmacies are also beginning to halt sales of the drugs until more is known about the levels of a likely carcinogen that regulators around the world have found in the medicines. (Edney, 9/30)

Sanofi, the company that makes Zantac, said in a statement that the FDA has found the amounts of the carcinogen NDMA in its drug 鈥渂arely exceed amounts found in common foods.鈥 鈥淲e are working closely with the FDA and are conducting our own robust investigations to ensure we continue to meet the highest quality safety and quality standards,鈥 the company said.聽(Sullivan, 9/30)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, August 7
  • Thursday, August 6
  • Wednesday, August 5
  • Tuesday, August 4
  • Monday, August 3
  • Friday, July 31
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • 51视频
  • Privacy Policy

漏 2026 51视频